These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18842531)

  • 21. Identifying and responding to depression in adult cancer patients: evaluating the efficacy of a pilot communication skills training program for oncology nurses.
    Brown RF; Bylund CL; Kline N; De La Cruz A; Solan J; Kelvin J; Gueguen J; Eddington J; Kissane D; Passik S
    Cancer Nurs; 2009; 32(3):E1-7. PubMed ID: 19295421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nurses lead the way in prostate cancer care.
    Krishnasamy M; Leahy M; Schubach K; Fraser C; Aranda S
    Aust Nurs J; 2007 May; 14(10):37. PubMed ID: 17539336
    [No Abstract]   [Full Text] [Related]  

  • 23. Bisphenol A may reduce the efficacy of androgen deprivation therapy in prostate cancer.
    Hess-Wilson JK
    Cancer Causes Control; 2009 Sep; 20(7):1029-37. PubMed ID: 19370395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer screening; is this a teachable moment?
    Brawley OW
    J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
    [No Abstract]   [Full Text] [Related]  

  • 26. Men's experience of their life situation when diagnosed with advanced prostate cancer.
    Jonsson A; Aus G; Berterö C
    Eur J Oncol Nurs; 2009 Sep; 13(4):268-73. PubMed ID: 19535293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uncertainty intervention for watchful waiting in prostate cancer.
    Bailey DE; Mishel MH; Belyea M; Stewart JL; Mohler J
    Cancer Nurs; 2004; 27(5):339-46. PubMed ID: 15525860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [What's new in 2008 in the field of basic and clinical research in prostate cancer?].
    Phé V; Rouprêt M; Salomon L; Soulié M
    Prog Urol; 2009 May; 19 Suppl 2():S29-42. PubMed ID: 19447327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of surgical care for prostate cancer in NSW, 1993-2002: rural/urban and socio-economic variation.
    Hayen A; Smith DP; Patel MI; O'Connell DL
    Aust N Z J Public Health; 2008 Oct; 32(5):417-20. PubMed ID: 18959543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 32. Cancer informational support and health care service use among individuals newly diagnosed: a mixed methods approach.
    Dubois S; Loiselle CG
    J Eval Clin Pract; 2009 Apr; 15(2):346-59. PubMed ID: 19335496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 34. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using archetypes and transitions theory to help patients move from active treatment to survivorship.
    Rancour P
    Clin J Oncol Nurs; 2008 Dec; 12(6):935-40. PubMed ID: 19064387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
    J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes and follow-up strategies for patients on active surveillance.
    Dall'Era MA; Carroll PR
    Curr Opin Urol; 2009 May; 19(3):258-62. PubMed ID: 19295434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of colorectal cancer and prostate cancer and impact of radiation therapy.
    Huo D; Hetzel JT; Roy H; Rubin DT
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1979-85. PubMed ID: 19531678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.